ANALYSIS OF THE EFFICIENCY OF PREVENTIVE TREATMENT OF PATIENTS WITH HEMOPHILIA IN THE AMUR REGION
The analysis of the results of treatment of patients with hemophilia living in the Amur region was carried out. There are 48 patients in the Amur Register of Hemophilia; with haemophilia A - 40 persons and with hemophilia B - 8 persons; adults - 27 persons and children - 21 persons. Since 2005, all patients with hemophilia in the Amur region receive preventive treatment. Both plasma and recombinant factor preparations are used. Preventive therapy has reduced the incidence of spontaneous bleeding in such patients by 98%. In the group of patients receiving individualized prophylaxis, the total number of infusions of the drug has significantly decreased (by 1 injection per week or 52 injections per year). Individualization of prevention allowed to increase the adherence of patients to therapy, due to the opportunity to consider the level of the physical activity. The Russian drug FVIII moroctocog alpha is as affective as foreign analogues and can be effectively used for the prevention of hemorrhage in hemophilia A, including the individual therapy.